NCT02612298

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate in Patients With Essential Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 198 (actual)
• Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy and safety of Arotinolol Hydrochloride and Metoprolol succinate on morning blood pressure, heart rate and target organ damage in patients with essential hypertension. To provide evidence for hypertension treatment. A group: Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks. B group: Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.

Detailed description

Compare the efficacy and safety of Arotinolol Hydrochloride and Metoprolol succinate on morning blood pressure, heart rate and target organ damage in patients with essential hypertension.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Arotinolol Hydrochloride	Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
DRUG	Metoprolol succinate sustained-release tablet	Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.

Timeline

• Start date: 2015-08-01
• Primary completion: 2018-09-13
• Completion: 2018-09-13
• First posted: 2015-11-23
• Last updated: 2019-04-17

Locations

1 site across 1 country: China